Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Delayed Quote. Delayed NASDAQ OMX COPENHAGEN - 11/27 10:59:53 am
2319 DKK   +0.52%
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/23/2020 11/24/2020 11/25/2020 11/26/2020 11/27/2020 Date
2276(c) 2210(c) 2252(c) 2307(c) 2319(c) Last
101 438 199 517 189 902 121 312 122 566 Volume
-0.70% -2.90% +1.90% +2.44% +0.52% Change
More quotes
Financials
Sales 2020 9 830 M 1 580 M 1 580 M
Net income 2020 4 665 M 750 M 750 M
Net cash position 2020 15 033 M 2 417 M 2 417 M
P/E ratio 2020 32,3x
Yield 2020 -
Sales 2021 8 076 M 1 299 M 1 299 M
Net income 2021 2 773 M 446 M 446 M
Net cash position 2021 15 390 M 2 474 M 2 474 M
P/E ratio 2021 54,2x
Yield 2021 -
Capitalization 152 B 24 374 M 24 389 M
EV / Sales 2020 13,9x
EV / Sales 2021 16,9x
Nbr of Employees 712
Free-Float 95,2%
More Financials
Company
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (58.8%); - income from research and development (34.8%); - other (6.4%): primarily income from partnership agreement. At the end of 2019, the group had a portfolio of 18 products in... 
Sector
Biotechnology & Medical Research
Calendar
12/05 | 03:45pmPresentation
More about the company
All news about GENMAB A/S
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24Genmab Announces Enapotamab Vedotin Update
GL
11/24GENMAB A/S : Mereo BioPharma Group plc - Mereo BioPharma Appoints Suba Krishnan,..
AQ
11/20IMMUNOPRECISE ANTIBODIES : and Genmab Enter into a Technology Partnership Target..
AQ
11/13GENMAB A/S : 2020 Virtual Capital Markets Day – November 13, 2020
PU
11/11GENMAB A/S : Articles of association dated November 10, 2020 – English
PU
11/11NOVARTIS : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/11NOVARTIS : Genmab to Present at Jefferies Virtual London Healthcare Conference
AQ
11/11GENMAB A/S : BioNTech Announces Third Quarter 2020 Financial Results and Corpora..
AQ
11/10GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/10GENMAB A/S : to Present at Jefferies Virtual London Healthcare Conference
AQ
11/06GENMAB A/S : Announces Phase 3 Study Evaluating Epcoritamab in Patients with Rel..
AQ
11/06GENMAB A/S : Announces that Janssen has submitted a Type II Variation Applicatio..
AQ
More news
News in other languages on GENMAB A/S
11/23Thanksgiving et Covid ne font pas bon ménage
11/23AVIS D'ANALYSTES DU JOUR : ASML, BMW, Crédit Suisse, Genmab, HelloFresh, Orsted,..
11/16Des idées d'ETF pour miser sur le retour en grâce des valeurs moyennes
11/16AVIS D'ANALYSTES DU JOUR : Adidas, Alcon, Continental, Engie, Neste, Scout24, St..
10/30GENMAB A/S : publication des résultats trimestriels
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Stock Trading Strategies
GENMAB A/S - 06/15
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | GMAB | DK0010272202 | MarketScreener
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 2 194,34 DKK
Last Close Price 2 319,00 DKK
Spread / Highest target 29,4%
Spread / Average Target -5,38%
Spread / Lowest Target -90,2%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Deirdre P. Connelly Chairman
Anthony Mancini Chief Operating Officer & Executive Vice President
Anthony Pagano Chief Financial Officer & Executive Vice President
Michael K. Bauer SVP, Head-Operations, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S56.53%24 374
WUXI APPTEC CO., LTD.56.53%37 916
BEIGENE, LTD.72.47%26 060
NEUROCRINE BIOSCIENCES, INC.-11.51%8 928
SPRINGWORKS THERAPEUTICS, INC.76.67%3 259
AXSOME THERAPEUTICS, INC.-27.26%2 808